A rise in methicillin-resistant S. aureus (MRSA) infections in hospitals and the population has led to an increase in Macrolide–Lincosamide–Streptogramin type B (MLSB) antibiotic resistance. This has led to increased treatment costs, length of hospital stay and morbidity, as therapy has grown increasingly challenging. As a result, it is imperative that S. aureus isolates and their susceptibility patterns especially to clindamycin and erythromycin, be accurately identified and reported. Of the 341 (100%) S. aureus strains that were recovered from various clinical samples, such as blood, pus, urine, and sputum, 267 (78.6%) were MSSA (methicillin-sensitive S. aureus) and 74 (21.4%) were MRSA. iMLSB (inducible MLSB) resistance detected by D-test was present in 42 (12.3%) isolates, out of which 23 (15.6%) were MSSA and 19 (33.9%) were MRSA. Real-time PCR was done for gene detection on all iMLSB positive isolates. The majority of the isolates – 22 (52.4%) showed both ermA and ermC genes; out of which  13 (56.5%)  were MSSA, whereas 9 (47.4%) were MRSA. To correctly identify the true phenotypes sensitive to clindamycin and those showing iMLSB resistance, a reasonably priced, D-test (double disc diffusion test)  can be included in routine antibiotic susceptibility testing in clinical settings for all erythromycin-resistant staphylococcal isolates. By following this technique, clinicians treating patients with infections brought on by inducible clindamycin-resistant strains will be guided to forego clindamycin from their treatment regimens, helping to prevent therapeutic failures.